Results 21 to 30 of about 6,247,272 (199)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Chemotherapy‐induced peripheral neuropathy remains a major complication in pediatric cancer, with disrupted somatosensory and nociceptive processing being a key aspect. This review synthesizes empirical studies on alterations in somatosensory and nociceptive processing in children and adolescents with cancer.
Julia Schweiger +4 more
wiley +1 more source
4d N $$ \mathcal{N} $$ = 1 from 6d D-type N $$ \mathcal{N} $$ = (1, 0)
Journal of High Energy Physics, 2020 Compactifications of 6d N $$ \mathcal{N} $$ = (1, 0) SCFTs give rise to new 4d N $$ \mathcal{N} $$ = 1 SCFTs and shed light on interesting dualities between such theories.
Jin Chen +3 more
doaj +1 more source
Названия мать-и-мачехи в удмуртских диалектах [The Names for Coltsfoot (Tussilago farfara L.) Used in Udmurt Dialects]; pp. 53-62 [PDF]
Linguistica Uralica, 2018 In this article the Udmurt dialect names for coltsfoot (Tussilago farfara L.) are discussed, their word-formation structure is analyzed, the etymology of their components is given and the basic naming principles are defined.
Marianna Rifovna Nasibullina
doaj +1 more source
Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya +10 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman +17 more
wiley +1 more source
Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy +5 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Neuropsychological complications may impair the qualitative prognosis of patients with pediatric brain tumors. However, multifaceted evaluations cannot be conducted in all patients because they are time consuming and burdensome for patients.
Ami Tabata +9 more
wiley +1 more source
Ibn Al-Haitham Journal for Pure and Applied Sciences, 2017 New complexes of first series of transition metals with P-amino benzene dithiocarbamate of the general formula [M(PABdtc)2] and [ M(PABdtc)2(L)n] M=Fe( ІІ ),Co( ІІ ),Ni( ІІ ) ,Cu(ІІ) and Zn (ІІ). PABdtc = Paraamino benzene dithiocarbamate ,n=2
Mohammed Jassim Mohammed +1 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson +20 more
wiley +1 more source